Reactions 431 - 12 Dec 1992

Antineoplastics

Secondary cancers in patients with Hodgkin’sdisease: incidence study

The risk of developing a secondary cancer was associatedwith various treatment- and patient-related factors in ananalysis of 12 411 patients from the International Database onHodgkin’s Disease who had survived at least 1 year post-treatment. There were 367 cases of solid tumour Cancers ofthe salivary gland, bronchus, pleura, skin (other thanmelanoma), small intestine (males only), bone (males only)and breast (females only) occurred at significantly higher ratesthan in the general population. An increased risk of solidtumour was associated with age > 40 years and extended fieldradiotherapy given alone or in combination with antineoplastictherapy. The cumulative incidence increased from 3.1% at 10years after start of treatment for Hodgkin’s disease to 6.2%after 15 years. Acute leukaemias and myelodysplasticdisorders numbered 158, again occurring at a significantlyhigher rate than in the general population. Age > 40 years andantineoplastic therapy with MOPP (chlormethine, vincristine,procarbazine and prednisone, or minor variations) either aloneor with radiotherapy correlated strongly with an increased riskof secondary leukaemia. The third group of secondary cancerswas non-Hodgkin’s lymphoma of which there were 106 casesassociated significantly with age > 30 years, radiotherapycombined with non-MOPP chemotherapy (mainlydaunorubicin-containing regimens) and any treatment forrelapse. The cumulative incidence rates were 1.4 and 1.6% forleukaemias and non-Hodgkin’s lymphoma respectively, at 15years after the start of treatmentHenry-Amar M. Second cancer after the treatment for Hodgkin’s disease: a reportfrom the International Database on Hodgkin’s disease. Annals of Oncology 3(Suppl. 4): 117-128, Sep 1992 - France 800169453

1

Reactions 12 Dec 1992 No. 4310114-9954/10/0431-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved